Literature DB >> 36107964

Photobiomodulation, as additional treatment to traditional dressing of hard-to-heal venous leg ulcers, in frail elderly with municipality home healthcare.

Marianne Degerman1, Micael Öhman2, Bo C Bertilson3,4.   

Abstract

The main objectives of the study were to explore whether laser Photobiomodulation (PBM) in addition to traditional dressing of hard-to-heal venous leg ulcer, reduced healing time of the ulcer and if the duration of the ulcer before PBM impacted the treatment time with PBM to healing. The intervention group was frail, elderly patients with home healthcare in the municipality of Skellefteå, registered in the Swedish quality registry RiksSar for ulcer treatment with hard-to-heal venous leg ulcer. The control group with equivalent physical conditions was obtained from the same quality registry. Definition of hard-to-heal ulcer was six weeks duration or more. The PBM was performed two times per week with laser type infrared GaAs, 904nm, 60mW, and 700Hz, targeting lymphatic area and ulcer area. Laser type red visible, GaAllnp, 635nm, 75mW and 250Hz, targeting ulcer area. The intervention group treated with PBM in addition to traditional dressing healed significantly faster than the control group with a mean of 123 days (p = 0.0001). Duration of the ulcer before PBM did not impact the healing time. To conclude, the findings indicate that using PBM in addition to dressing may have multiple benefits on hard-to-heal venous leg ulcer, saving valuable time and resources for patients, healthcare providers, and institutions.

Entities:  

Mesh:

Year:  2022        PMID: 36107964      PMCID: PMC9477261          DOI: 10.1371/journal.pone.0274023

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.752


Introduction

Wound healing is a dynamic process consisting of four continuous, overlapping, and precisely-programmed phases. Interruptions or prolongation in the process can lead to delayed or impaired wound healing and hard-to-heal ulcers (HHU). Factors affecting prevalence of HHU and wound healing include local and systemic factors. Local factors that directly influence the characteristics of the wound include oxygenation, infection, foreign body, and venous sufficiency. Systemic factors include the overall health or disease state of the individual that affect the ability to heal such as age, gender, ischemia, comorbidities, immunocompromised conditions, obesity, and nutrition to mention a few [1, 2]. Older adults are more likely to develop HHU than younger individuals. The effect of age and comorbidity on the effectiveness of existing and emerging treatments for HHU are unknown as older adults tend to be excluded from randomized clinical trials [1, 3]. There has been a rapid increase of the incidence and prevalence of HHU globally, with a majority of hard-to-heal leg ulcers of different aetiologies such as venous ulcers, pressure ulcers, and arterial ulcers [4-7]. Venous aetiology is the primary underlying factor in 70% of the HHU [8]. Long-term healing prognosis for HHU is poor, and worst for venous leg ulcers (VLU) [9]. Recurrence of VLU after healing 60–70% and the highest rate of recurrence within the first three months after healing [8, 10–12]. HHU have considerable economic and care resource impacts on the healthcare system, especially in outpatient settings [13, 14]. Various studies stress the importance of a holistic assessment and risk factor reduction in addressing the complex issues of HHU, especially in older adults [1-5]. PBM delivered using low-intensity laser has been shown to have the potential to improve wound healing and reduce pain, inflammation, oedema, and to regenerate damaged tissue such as wounds, bones, and tendons. PBM is a light therapy of low power intensity with a non-thermal process in tissue. Studies have shown that PBM induces a photochemical reaction at the cell and tissue level that affects three of the wound healing phases: the inflammatory phase, the proliferative phase, and the remodelling phase, and allows wound sites to close more rapidly. In addition, PBM is a non-invasive treatment with no known negative side effects [15-22]. The Swedish national quality registry RiksSar for ulcer treatment includes patients with HHU of different aetiologies. In 2020, the registry had a total of 20,242 registrations: 35% made by specialist units of hospital care, 43% by primary healthcare centres, and 22% by municipality primary home healthcare. The registry was started in 2009 [23]. The objectives of the study were to explore: If PBM, in addition to traditional dressing of hard-to-heal VLU in frail elderly patients in municipality home healthcare, improves healing time of the VLU compared to a control group receiving traditional dressing only. The possible impact of duration of the VLU, before PBM, on healing time.

Materials and methods

This is a retrospective study from the Swedish quality registry RiksSar for ulcer treatment. The study was approved by the Ethical committee of Medicine in Lund Sweden with number 2020–02194. A written consent was obtained from the participant or the legal representative in the case of impaired cognition in the intervention group, the details of consent were declared in the application to the Ethical committee. The intervention group consisted of patients in the municipality of Skellefteå with hard-to-heal VLU registered in RiksSar and treated by the home healthcare department during April 2019 to September 2020. Inclusion criteria were frail elderly patients risk-assessed and treated according to the guidelines in the quality register Senior Alert [24]. Patients were continuously admitted to municipality home healthcare throughout the study. Exclusion criteria were: Non-improvement: no visible reduction of ulcer size after six weeks of PBM, and no qualitative measures of an active healing process. One VLU was excluded due to non-improvement. Personal choice: patients’ personal decision to interrupt PBM. Four VLU´s were excluded due to personal choice. Decease of the patient during the treatment period. Four VLU´s were excluded due to decease. Sars Covid-19 pandemic: six VLU´s were excluded due to circumstances connected to the pandemic. The VLU´s in the intervention group with exclusion criteria 2–4 showed healing in progress until exclusion. The remaining intervention group consisted of 34 VLU´s in 27 patients. To enable a control group, the VLU registrations in the RiksSar registry were used. Table 1 show patients in the RiksSar registry stratified into four groups A, B, C, D, according to duration of VLU in days, also the respective number of VLU´s being in treatment, having resulted in amputation, deceased, or having healed. The number of healed VLU diminished with duration and the risk of decease was considerably higher in group D, duration of 490 days or more. Patients with status healed VLU were selected as control group for this study.
Table 1

The RiksSar registry stratified into four groups (A-D) according to duration of the venous leg ulcer (VLU), also the respective number of VLU´s being in treatment, having resulted in amputation, deceased or having healed.

GroupDuration of VLU (days)Group characteristicsIn treatmentAmputatedDeceaseHealedTotal
A0–123Number1100193204
Female %2761
Age mean7978
B124–230Number300196199
Female %3368
Age mean7780
C231–490Number1505190210
Female %53068
Age mean808180
D>490Number121484107316
Female %626261
Age mean798579
TotalNumber150489686929
The control group consisted of VLU dressed according to physicians’ orders until healing occurred. Data extracted were ulcer area and patient age in the same range as for the intervention group, as well as gender, comorbidity and presence of diabetes. A total of 639 VLU´s in 531 patients from RiksSar were included. 47 VLU´s were excluded. A conscious choice was made to allow a difference between the group’s ulcer area and patient age to be able to preserve as many VLU´s as possible in the control group.

Treatment procedure

Each VLU was treated according to physicians’ orders based on the national recommendations for VLU treatment [25]. During the study, the VLU was photographed every week and its length and width was measured every three weeks until healing was obtained. The PBM treatment procedure and dosing parameters were based on clinical experience of the patient group. Each VLU was treated two times per week, with an interval of two and three days. PBM equipment dose was calibrated in accordance with the manufacturer’s instructions before the study, every six months during the study, and after the completed study. The treatment team consisted of four healthcare trained specialists in ulcer treatment, with supervised PBM training and were given written treatment procedure with guidelines. The ulcer was first cleaned with 9 mg/ml NaCl solution and then treated with both infrared and red PBM. Infrared PBM was administered with a 904nm, 60mW, GaAs laser with pulse frequency of 700Hz to treat targeted lymphatic area and ulcer area. The PBM treatment started at shoulder/ neckline for 2 minutes, dose 2.4J/cm2 bilateral and then in the hollow of the knee for 2 minutes, dose 2.4 J/cm2. Intact skin close to the VLU was thereafter treated during 30 seconds per location above, below, and on each side of the VLU dose 0.6/cm2, with contact application technique. Finally, the VLU surface was treated at a distance of 1cm with projection application technique, for 2 minutes per position until the total surface was treated with a dose of 2.4 J/cm2. Red visible PBM was administered with a 635nm, 75mW, GaAllnp laser with pulse frequency of 250Hz to the ulcer edges 30 seconds per position with a dose of 0.8 J /cm2 and stepwise moved 1cm between positions with contact application technique, until the total ulcer edge was treated. The VLU surface was treated at a distance of 1cm with projection application technique, for 2 minutes per position until the total surface was treated with a dose of 3.1 J/cm2. After the treatment with infrared and red PBM, the VLU was dressed according to physicians’ orders.

Statistical analysis

Due to the heterogeneity of the intervention group, an individual control group for each of the 34 VLU´s in the intervention group was extracted from the control group. VLU´s in the individual control group had the same or longer healing time, than the intervention VLU duration when PBM started. This resulted in a total of 34 individual control groups, all different in number of ulcers. The 34 individual control groups showed a large difference in number of observations of healing time between each other. To eliminate the bias caused by these large differences in number, the subsequent analysis is based on the observed 34 median differences in time to heal between the intervention group and the individual control groups. The 34 median values were used as observations in a Wilcoxon signed rank test to analyze if there was a statistically significant difference, with alpha value set to 0.01. The null hypothesis was: There is no difference in healing time between the intervention group and the control group. The possible impact of ulcer duration before PBM for healing time with PBM was statistically analyzed using Pairwise Correlation analysis and Mahalanobis Distances analysis of the sensitivity toward outliers.

Results

Characteristics of the intervention and the control group

Women accounted for 85% of the intervention group and 67% of the control group. Comorbidities in the intervention group were three diagnoses and two in the control group. Diabetes was found in 44% of the patients in the intervention group and in 21% of the patients in the control group. Table 2 shows the characteristics of the VLU´s and the patients in the intervention group and the control group as well as difference in healing time between the intervention group being treated with PBM and the controls.
Table 2

Characteristics of the venous leg ulcers (VLU´s) and the patients in the intervention group and the control group as well as difference in healing time between the intervention group being treated with Photobiomodulation (PBM) and the controls.

Intervention GroupControl GroupMean difference in healing time (days)
VLUPatient age (years)Gender (Female/Male) (Female = F/Male = M)Comorbidities (Count)Diabetes (Yes/No)VLU area (cm2)VLU days before PBMPBM time to healing (days)Mean number of VLUMean patient age (years)Share of Females (%)Mean number of comorbiditiesDiabetes (%)Mean VLU area (cm2)Mean healing time (days)
01 75F3N5427639806722144197148
02 75F3N14233639806722144197122
03 97F3N2492862880672214201124
04 90F2N6636618806722144204135
05 75F2N477845808067221422463
06 86F3N21122849181672214257117
07 94F2N2112574918167221425788
08 78F5Y11197947481672224426668
09 84F3N301401404368167222442899
10 91M3Y915428409816722255295113
11 69M3N13161206395816722355303-64
12 69M3N56161148395816722355303-6
13 85F2N216125395816722355303117
14 83F4Y91685438281672235531088
15 83F4Y101686138281672235531081
16 83F4Y51686138281672235531081
17 85F3N418226354816622355333125
18 85F3N818235354816622355333116
19 85F3N118235354816622355333116
20 85F3N32593724581653235420124
21 91F2N144835107826431655692209
22 83F5N11630505982642145977297
23 90F5N71953313883753132222797531
24 65M2Y11102249268362219101604533
25 62F2Y45610562380672214420342
26 62F2Y200301911998264322547482
27 62F2Y1503011471998264322547426
28 82F3Y28701459980672214210126
29 73F4Y20635661880672214420485
30 73F4Y95614623806722144203133
31 90M3Y124214639806722144197141
32 87F3N9494262880672214201110
33 88F4Y63221191858263323550261
34 88F4Y31401124368167222428937
Median age in the intervention group was 84 years and in the control group 80 years. The ulcer area in the intervention group was a median of 4 cm2 and in the control group 7 cm2. Table 3 shows the patient age and ulcer area distribution in the intervention group and the control group, with mean age, mean area, and its standard deviation and number of observations per category.
Table 3

Patient age and ulcer area distribution in the intervention group (IG) and the control group (CG).

Quantiles
LevelMin.25%Median75%MaxMeanStd DevNo obs
AgeIG6074848797801034
(years)
AgeCG6874808596800.3639
(years)
Ulcer AreaIG13711200194234
(cm2)
Ulcer AreaCG1241056911639
(cm2)

Std Dev = Standard deviation, No obs. = Number of observations.

Std Dev = Standard deviation, No obs. = Number of observations. Distribution of numbers of VLU´s in the 34 individual control groups: median number was 402 VLU´s and mean number was 411 VLU´s per individual control group. S1 Fig.

Healing time of VLU in the intervention and the control group

Healing time of the 34 hard-to-heal VLU´s in the intervention group receiving PBM was reduced between 66 and 180 days, with a mean of 123 days compared to the VLU´s in the control group receiving traditional dressing (p = 0.0001). S2 Fig.

Possible impact of duration of the VLU´s, before PBM, on healing time

Duration of the VLU´s before PBM, did not affect the PBM healing time. The observed dependence, in terms of linear correlation, between VLU duration before PBM for the healing time with PBM is = 0.6. The diagram shows an absence of observations in a wide range between the most extreme observation and the rest. By excluding the three most extreme observations, identified by Mahalanobis distances, the linear correlation decreased to = 0.23. Fig 1.
Fig 1

Dependence between venous leg ulcer (VLU) duration in days before photobiomodulation (PBM) and PBM time in days to heal VLU and linear correlation, 34 observations.

Discussion

In this study, it was found that the hard-to-heal VLU´s of the patients in the intervention group which received the added PBM treatment, healed significantly faster than the VLU´s of the control group (p = 0.0001). The mean difference in healing time was 123 days. This pronounced difference indicates a great potential for the PBM treatment. The intervention group exhibited a higher level of frailty than the control group being older, having more comorbidities including a larger percentage of diabetes. In defiance of those poorer circumstances the hard-to-heal VLU´s in the intervention group healed at least 66 days faster than the VLU´s of the control group. The possible impact of duration of the VLU´s before intervention with PBM was found to have a correlation of 0.6. However, the correlation was foremost caused by one single observation. By using the Mahalanobis Distances and excluding the three most extreme observations, the correlation decreased to 0.23. This indicates that the duration of the VLU before intervention with PBM treatment, may be regarded as a poor indication to predict treatment time with PBM. Previous perceptions and studies state diminishing probability of ulcer healing the longer the duration of the VLU [9]. The findings in this study suggest that PBM may provide a new approach in the treatment of hard-to-heal and long-term hard-to-heal VLU adding encouragement and a treatment tool for patients and professionals struggling with VLU treatment. This study, in accordance with other studies of PBM treatment, found beneficial effects on ulcer healing [15-22]. However, the biological and biochemical effects and mechanisms of PBM are still under investigation [15-17]. Different PBM irradiation and wavelengths have been evaluated in various studies with the aim to optimize PBM treatment [18, 19]. PBM in the range of 390–685 nm have been identified to affect superficial tissue, and longer wavelengths 808–904 nm are identified to stimulate deep-seated tissues. Whether to use red or near infrared light or a combination of both is also under investigation. Studies have compared different wavelengths or chosen to use a specific light to treat ulcers, and there is no agreement on the optimal application [18-22]. In this study, a combination of red and infrared light was used. The aim was to stimulate growth factors in the superficial tissue and increase circulation in deep tissue. In the home healthcare environment treatment time is a key. The risk of a too low dose to reach a result of PBM was identified as a greater risk than the risk of a too high dose that in other studies has shown to be less effective [15]. The treatment procedure and PBM dose in this study was standardized to be adequate, simple, and accessible to perform in the home healthcare environment. Our findings indicate that the combined treatment was successful. A strength in this study was the possibility to compare healing time and other data with the large Swedish registry RiksSar and to tailor individual control groups for every VLU treated with PBM, resulting in a mean of 411 comparisons per treated VLU. Another strength is the possibility to follow the study cohort in home healthcare until healing. Limitations of our study include the lack of a randomization of different treatment doses including placebo. Another limitation was the lack of laboratory tests to ascertain biochemical healing processes. Further studies are needed to determine if there are optimal PBM treatment doses for different patient categories, and also investigate the durability of PBM in VLU treatment and biological reactions in the frail elderly body and the VLU´s.

Conclusions

Regardless of the frailty of the intervention group, PBM, in addition to traditional dressing, significantly improved healing time of hard-to-heal VLU´s with a mean of 123 days, compared to the control group. The duration of the VLU before initiating PBM treatment did not affect healing time with PBM. Incorporating PBM into mainstream VLU treatment may significantly change outcomes of treatment. Shortening ulcer duration and promoting healing, including long-term hard-to-heal VLU saves time and resources, for patients, professionals, and healthcare institutions.

Distribution of numbers of VLU in the 34 individual control groups.

Distribution of numbers of VLU in the individual control groups. X-axis = number of control group VLU. Y-axis number of individual control groups. (PDF) Click here for additional data file.

Healing time of VLU in the intervention and control group.

Distribution median difference in healing time intervention and control group VLU. (PDF) Click here for additional data file.
  22 in total

1.  Prevalence and factors associated with chronic wounds in older adults in primary care.

Authors:  Chrystiany Plácido de Brito Vieira; Telma Maria Evangelista de Araújo
Journal:  Rev Esc Enferm USP       Date:  2018-12-20       Impact factor: 1.086

2.  Recurrence of leg ulcers within a community ulcer service.

Authors:  C J Moffatt; M C Dorman
Journal:  J Wound Care       Date:  1995-02       Impact factor: 2.072

3.  Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies.

Authors:  Laura Martinengo; Maja Olsson; Ram Bajpai; Michael Soljak; Zee Upton; Artur Schmidtchen; Josip Car; Krister Järbrink
Journal:  Ann Epidemiol       Date:  2018-11-12       Impact factor: 3.797

4.  Predicting the likelihood of venous leg ulcer recurrence: The diagnostic accuracy of a newly developed risk assessment tool.

Authors:  Kathleen J Finlayson; Christina N Parker; Charne Miller; Michelle Gibb; Suzanne Kapp; Rajna Ogrin; Jacinta Anderson; Kerrie Coleman; Dianne Smith; Helen E Edwards
Journal:  Int Wound J       Date:  2018-03-13       Impact factor: 3.315

5.  Cost-of-illness studies in chronic ulcers: a systematic review.

Authors:  B Chan; S Cadarette; W Wodchis; J Wong; N Mittmann; M Krahn
Journal:  J Wound Care       Date:  2017-04-01       Impact factor: 2.072

Review 6.  Venous ulcer: epidemiology, physiopathology, diagnosis and treatment.

Authors:  Luciana P Fernandes Abbade; Sidnei Lastória
Journal:  Int J Dermatol       Date:  2005-06       Impact factor: 2.736

Review 7.  Factors affecting wound healing.

Authors:  S Guo; L A Dipietro
Journal:  J Dent Res       Date:  2010-02-05       Impact factor: 6.116

Review 8.  Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring.

Authors:  Pinar Avci; Asheesh Gupta; Magesh Sadasivam; Daniela Vecchio; Zeev Pam; Nadav Pam; Michael R Hamblin
Journal:  Semin Cutan Med Surg       Date:  2013-03

9.  Effects of the Low-Level Laser Therapy (LLLT) in the process of healing diabetic foot ulcers.

Authors:  Maura Cristina Porto Feitosa; Ana Flávia Machado de Carvalho; Valrian Campos Feitosa; Isabely Madalena Coelho; Rauirys Alencar de Oliveira; Emília Ângela Loschiavo Arisawa
Journal:  Acta Cir Bras       Date:  2015-12       Impact factor: 1.388

10.  Epidemiology of chronic wounds in Germany: Analysis of statutory health insurance data.

Authors:  Kristina Heyer; Katharina Herberger; Kerstin Protz; Gerd Glaeske; Matthias Augustin
Journal:  Wound Repair Regen       Date:  2016-04-01       Impact factor: 3.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.